Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2717-2721

  Rahman, Zia ^a   Kavanagh, John ^a   Champlin, Richard ^a   Giles, Richard ^a   Hanania, Elie ^a   Fu, Siqinq ^f   Zu, Zifei ^a   Mehra, Rakesh ^a   Holmes, Frankie ^a   Kudelka, Andrzej ^a   Claxton, David ^a   Verschraegen, Claire ^a   Gajewski, James ^a   Andreeff, Michael ^a   Heimfeld, Shelly ^b   Berenson, Ronald ^b   Ellerson, Debra ^a   Calvert, Leslie ^a   Mechetner, Eugene ^c   Holzmayer, Tanya ^c   Dayne, Andrew ^c   Hamer, Joy ^a   Bachier, Carlos ^a   Ostrove, Jeffrey ^d   Przepiorka, Donna ^a   Burtness, Barbara ^f   Cote, Richard ^e   Bast, Robert ^a   Hortobagyi, Gabriel ^a   Deisseroth, Albert ^a,f,g   more..

^a UNIVERSITY OF TEXAS   (United States)

^b Cell Pro Inc   (United States)

^c Ingenex Inc   (United States)

^d Magenta Corporation   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f YALE CANCER CENTER   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; PACLITAXEL; THIOTEPA;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; METASTASIS; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; P-GLYCOPROTEIN; PACLITAXEL; TRANSPLANTATION, AUTOLOGOUS;

EID: 0031782881     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Teicher, B. A., Holden, S. A., Cucchi, C. A., Cathcart, K. N. S., Korbut, T. T., Flatow, J. L., and Frei, E., III. Combination of N,N′,N″-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res., 48: 94-100, 1988.
2. Skipper, H. E., and Schabel, F. M. Quantitative and cytokinetic studies in experimental tumor systems. In: J. Holand and E. Frei (eds.), Cancer Medicine, pp. 663-684. Philadelphia: Lea and Febiger. 1982.
3. Hryniuk, W., and Levine, M. N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol., 4: 1162-1170, 1986.
4. Hryniuk, W., and Bush, H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2: 1281-1288. 1984.
5. Tannock, I. F., Boyd, N. F., Deboer, F., Erlichman, C., Fine, S., Larocque, G., Mayers, C., Perrault, D., and Sutherland, H. A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J. Clin. Oncol., 6: 1377-1387, 1988.
6. Jones, R. B., Holland, J. F., Bhardwal, S., Norton, L., Wilfinger, C., and Strashun, A. A Phase I-II study of intensive-dose adriamycin for advanced breast cancer. J. Clin. Oncol., 5: 172-177, 1987.
7. Huan, S., Yau, J., Wallerstein, R., Dunphy, F., Spencer, V., Williams, D., LeMaistre, C., Deisseroth, A., Hortobagyi, G., Buzdar, A., Theriault, R., Spinolo, J., Dicke, K., and Spitzer, G. Characteristics of long-term progression free survivors after tandem high-dose cyclophosphamide, etoposide and cisplatin (CVP) for breast cancer patients (PTS). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 10: 60, 1991.
8. Dunphy, F. R., Spitzer, G., Fornoff, J. E., Yau, J. C., Huan, S. D., Dicke, K. A., Buzdar, A. U., and Hortobagyi, G. N. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer (Phila.), 73: 2157-2167, 1994. [Erratum. Cancer (Phila.), 74: 773, 1994].
9. Hanania, E., Fu, S., Zu, Z., Hegewisch-Becker, S., Korbling, M., Hesterr, J., Durett, A., Andreeff, M., Mechetner, E., Holzmayer, T., Roninson, I., Giles, R. E., Berenson, R., Heimfeld, S., and Deisseroth, A. B. Chemotherapy resistance to Taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther., 2: 285-294, 1995.
10. Hanania, E. G., Fu, S., Roninson, I., Zu, Z., and Deisseroth, A. Resistance to Taxol chemotherapy produced in mouse marrow cells by safety-modified retrovirus containing a human MDR-1 transcription unit. Gene Ther., 2: 279-284, 1995.
11. Podda, S., Ward, M., Himelstein, A., Richardson, C., De la Flor-Weiss, E., Smith, L., Gottesman, M., Pastan, I., and Bank, A. Transfer and expression of the human multiple drug resistance gene into live mice. Proc. Natl. Acad. Sci. USA, 89: 9676-9680, 1992.
12. Sorrentino, B. P., Brandt, S. J., Bodine, D., Gottesman, M., Pastan, I., Cline, A., and Nienhuis, A. W. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR-1. Science (Washington DC), 257: 99-101, 1992.
13. Hanania, E. G., Giles, R. E., Kavanagh, J., Ellerson, D., Zu, Z., Wang, T., Su, Y., Dudelka, A., Rahman, Z., Holmes, F., Hortobagyi, G., Claxton, C., Bachier, C., Thall, P., Cheng, S., Hester, J., Ostrove, J., Byrd, R., Cheng, A., Korbling, M., Seong, D., Cote, R., Holzmayer, T., Mechetner, E., Heimfeld, S., Berenson, R., Burtness, B., Edwards, C., Bast, R., Andreeff, M., Champlin, R., and Deisseroth, A. B. Results of MDR-1 modification trial indicate that CFUGM do not contribute to post transplant hematopoietic recovery following intensive systemic therapy. Proc. Natl. Acad. Sci. USA, 93: 15346-15351, 1996.
14. Hanania, E. G., and Deisseroth, A. B. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther., 1: 21-25, 1994.
15. Deisseroth, A. B., Zu, Z., Claxton, D., Hanania, E. G., Fu, S. X., Ellerson D, Goldberg, L., Thomas, M., Janicek, K., Anderson, W. F., Hester, J., Korbling, M., Durett, A., Moen, R., Berenson, R., Hermfield, S., Hama, J., Calvert, L., Tibbits, P., Talpaz, M., Kantarjian, H., Champlin, R., and Reading, C. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood, 83: 3068-3076, 1994.
16. Hanania, E. G., Giles, R. E., Claxton, D., Zu, Z., Bachier, C., Hamer, J., Ellerson, D. X., Wang T, Su, Y., Haley, T., Kavanagh, J., Calvert, L., Rahman, Z., Holmes, F. X., Heimfeld S, Berenson, R., Holzmayer, T., Mechetner, E., Champlin, R. X., and Deisseroth AB. Post-transplant frequency of genetically modified cells using retroviral-mediated multiple drug resistance (MDR-1) stromal transduction protocol in breast and ovarian cancers. Proc. Am. Assoc. Cancer Res., 37: A2363, 1996.
17. Bonadonna, G., Zambetti, M., and Valagussa, P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. J. Am. Med. Assoc., 273: 542-547, 1995.
18. Amman, K., Rowlings, P. A., Vaughan, W. P., Pelz, C. J., Fay, J. W., and Fields, K. K. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J. Clin. Oncol., 15: 1870-1879, 1997.